The largest database of trusted experimental protocols

6 protocols using hepatocyte growth factor (hgf)

1

Hepatocyte Differentiation and Wnt/β-catenin Modulation

Check if the same lab product or an alternative is used in the 5 most similar protocols
HPCs were grown to confluence in complete medium, resuspended with trypsin-EDTA and cultured in differentiation medium for 7 days. The differentiation medium included DMEM/F12 medium (HyClone, SH30023.01B, USA) supplemented with 20% Matrigel (BD, 354230, USA), 40 ng/mL oncostatin M (Sino Biological Inc, 50112-M08H, China), 20 ng/mL hepatocyte growth factor, 10 ng/mL fibroblast growth factor 4 (Sino Biological Inc, China), and 10−7 mol/L dexamethasone (Schwartz et al. 2002 (link); Kamiya et al. 2009 (link)). To activate the Wnt/β-catenin signaling pathway, HPCs were treated with 4-benzyl-2-methyl-1,2,4-thiadiazolidine-3,5-dione (TDZD-8) (ApexBIO, B1249, USA) at a final concentration of 2.0 µΜ once a day. To inhibite the Wnt/β-catenin signaling pathway, HPCs were treated with recombinant mouse GSK3β protein (Sino Biological, 50650-M07B-50, USA,) at a final concentration of 100 ng/mL once a day.
+ Open protocol
+ Expand
2

Optimizing PILC Differentiation from pADSCs

Check if the same lab product or an alternative is used in the 5 most similar protocols
A one-step procedure for PILC differentiation was modified from a previous study [36 (link)]. Briefly, pADSCs were seeded (6 x 104/cm2) onto chitosan-coated or regular (or TCPS, tissue culture polystyrene, Corning, NY, USA) plates for one day and the medium was replaced with differentiation medium consisting of serum-free DMEM/F12 in the presence of 10 mM nicotinamide (Sigma N0636), 1 μM exendin-4 (Sigma E7144), 2 nM activin A (ProSpec, Ness Ziona, Israel), 10 nM pentastrin, 123 pM hepatocyte growth factor (Sino Biological Inc., Beijing, China), 1% B27, N2 supplement (Invitrogen, Carlsbad, CA, USA) and 17.5 mM glucose. Plates were cultured in air containing 5% CO2 for three days. Unless otherwise indicated, reagents were from Sigma-Aldrich. After three days, the glucose concentration was changed to 5.5 mM for the rest of differentiation period of 15 days with medium changed every three days.
+ Open protocol
+ Expand
3

High-Throughput Serological Protein Profiling

Check if the same lab product or an alternative is used in the 5 most similar protocols
ELISA plates (Nunc) were coated with 50 μl/well of human proteins in TBS-T (0.1% Tween) overnight at 4° C. The concentrations were: 3 μg/ml for L1CAM (Sino Biological), 1.5 μg/ml for DEL-1 (R&D), 2 μg/ml for angiopoietin-1 (R&D), 0.5 μg/ml for angiopoietin-2 (R&D), 1 μg/ml for vascular endothelial growth factor-A (Peprotech), 3 μg/ml for progranulin (R&D), 0.4 μg/ml for platelet derived growth factor-BB (eBioscience), and 1 μg/ml for hepatocyte growth factor (Sino Biological). Plates were washed and blocked for 1.5 hours at room temperature with 100 μl/well of protein-free blocking buffer (PFB) (0.1% Tween, Pierce, Cat# 37570). Patient sera diluted 1:2000 in PFB-T were added at 50 μl/well in triplicate for 1 hour at 4° C. After washing, 50 μl/well of an HRP-conjugated anti-human IgG (Fab)2 diluted 1:2000 (Southern Biotech, Cat# 6005-05)) was added for 1 hour at room temperature. The plates were washed and 50 μl/well of biotinylated Tyramide (10 μl/ml in amplification diluent concentrate diluted 1:1 with ddH2O, ELAST, PerkinElmer) was added for 30 minutes at room temperature. After washing, wells were incubated with streptavidin-HRP (50 μl/well, concentration of 2 μl/ml) in 1% BSA-PBS-T (0.1% Tween) for 30 min at room temperature. The plate was developed with pNPP substrate (Sigma-Aldrich) and the absorbance measured at 450 nm.
+ Open protocol
+ Expand
4

Signaling Pathway Inhibition Assay

Check if the same lab product or an alternative is used in the 5 most similar protocols
All antibodies used in this study are described in Supplementary Table S3. Cycloheximide, bafilomycin A1, and MG132 were from Sigma-Aldrich, whereas gefitinib was purchased from MedChem Express. EGF and HGF were from Sino Biological.
+ Open protocol
+ Expand
5

Hepatic Differentiation of Cord-Derived MSCs

Check if the same lab product or an alternative is used in the 5 most similar protocols
The third passage cultured cells were harvested at a density of 1 × 105 cells/well until 70%-80% confluence was reached and then seeded in DMEM/F12 medium supplemented with 20 ng/mL epidermal growth factor (EGF, Sino Biological, China) and 10 ng/mL basic fibroblast growth factor (bFGF, Sino Biological, China) for two days. To induce hepatic differentiation, this study drew upon the previously reported three-step protocol designed for human umbilical cord-derived MSCs [18 (link)]. The step-1 induction medium consists of DMEM/F12 supplemented with 20 ng/mL hepatocyte growth factor (HGF, Sino Biological), 10 ng/mL bFGF (Sino Biological, China), and 0.61 g/L nicotinamide (NTA, Sigma-Aldrich, USA) for 7 days. Thereafter, the cells were treated by a maturation medium including DMEM/F12 supplemented with 20 ng/mL oncostatin M (OSM, Sino Biological, China), 1 μmol/L dexamethasone (Dexa, Solarbio, China), and insulin-transferrin-selenium premix (ITS, Sigma-Aldrich, USA) for an additional week. The culture medium was replaced with fresh medium twice a week.
+ Open protocol
+ Expand
6

Purification and Characterization of Verticillin A

Check if the same lab product or an alternative is used in the 5 most similar protocols
Verticillin A was purified from wild mushroom with a purity of >99% as previously described.17 (link) C75 and palmitate were purchased from Sigma–Aldrich (St Louis, MO, USA). HGF was purchased from Sino Biological (Beijing, China). The primary antibodies for c-Met, p-c-Met (Y1234/1235), FAK, p-FAK (Y925), Src and p-Src (Y416) were obtained from Cell Signaling Technology (Danvers MA, USA). The primary antibody for β-actin was obtained from Sigma–Aldrich, and HPR-conjugated secondary antibodies were obtained from Santa Cruz Biotechnology (Santa Cruz, CA, USA).
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!